T. Kurent

Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label

A. Gils, M. Ferrante, G. Novak, 2020, European journal of gastroenterology & hepatology.

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease

G. Novak, J. Hanžel, Polona Švegl, 2019, Alimentary pharmacology & therapeutics.

Success and safety of high infliximab trough levels in inflammatory bowel disease

J. Osredkar, R. Orel, G. Novak, 2018, Scandinavian Journal of Gastroenterology.

Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn’s disease

G. Novak, J. Hanžel, I. Grabnar, 2021, European journal of gastroenterology & hepatology.

Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.

Debby Thomas, G. Novak, J. Hanžel, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

A. Gils, G. Novak, J. Hanžel, 2019, United European gastroenterology journal.

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model

Debby Thomas, G. Novak, J. Hanžel, 2021, Pharmaceutics.

The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease

J. Osredkar, K. Kumer, T. Fabjan, 2021, Biochemia medica.

Endoscopic Postoperative Recurrence In Crohn's Disease After Curative Ileocecal Resection With Early Prophylaxis By Anti-Tnf, Vedolizumab Or Ustekinumab: A Real-World Multicenter European Study.

J. Gisbert, E. Savarino, K. Farkas, 2022, Journal of Crohn's & colitis.

Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis

G. Novak, J. Hanžel, N. Zidar, 2023, European journal of gastroenterology & hepatology.